A Phase 3 interventional study of Cebranopadol 400 ug and Cebranopadol 200 ug in Acute Pain, sponsored by Tris Pharma, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.
Among the 351 studies in Acute Pain with a site in United States, this one is the 52nd largest by enrollment of the 320 interventional ones that give a count, is one of 27 that started in 2024, is one of 42 in phase 3, and was the 316th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Aponia Laboratories, Inc. · Sites in United States, Germany
Ages 18–65
Florida State University · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–40
Ochsner Health System · Sites in United States
Ages 35+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 63 · Phase 3 48 · Phase 4 66
First in 2001; this study’s year is marked. 27 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 279 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 84 across the 320 interventional studies, 100 across the 31 observational. Of the 265 that completed or were terminated, 132 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 351 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 2 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
31 of the studies in Acute Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07930559Phase 3Aponia Laboratories, Inc.Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | 2027-06 |
| NCT07511816Eli Lilly and CompanyA Study of LY4515100 in Participants With Pain Following Third Molar Removal | 2026-11 |
| NCT05335070Rutgers, The State University of New JerseyReducing Pain From Wisdom Molar Extractions | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
| NCT05458037Women and Infants Hospital of Rhode IslandRCT of Pain Perception With Fast and Slow Tenaculum Application | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Acute Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
This study is a Phase 3, multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain after Full Abdominoplasty. This study will be conducted in 3 phases: Screening, Treatment, and Follow-up.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cebranopadol 400 ug (once daily for 2 days)
Drug: Cebranopadol 400 ug
Cebranopadol 400 ug on Day 1; 200 ug on Day 2
Drug: Cebranopadol 400 ug · Drug: Cebranopadol 200 ug
Placebo (once daily for 2 days)
Drug: Placebo
Once daily
Also known as: TRN-228
Once daily on Day 2
Also known as: TRN-228
Once daily for 2 days
Primary Outcome Measure
Pain Numerical Rate Scale (NRS) area under the curve from 4 through 48 hours (AUC4-48)
Time frame: 4-48 hours
Secondary Outcome Measure:
Pain Numerical Rate Scale (NRS) AUC4-24
Time frame: 4-48 hours
Secondary Outcome Measure:
Number of doses of rescue medication
Time frame: 48 hours
Secondary Outcome Measure:
Pain NRS AUC
Time frame: 24-48 hours
Other Secondary Endpoint
Pain NRS
Time frame: Partial AUCs: 4-12, 12-24, 24-36, 36-48, and 4-36 hours
Other Secondary Endpoint
Rescue Medication
Time frame: Proportion of subjects who take at least 1 dose of rescue medication up to hours 12, 24, and 36
Other Secondary Endpoint
MOAA/S
Time frame: peak sedation, total score and AUC4-48
Ran from Sep 2024 to primary completion in Dec 2024, 3 months.
Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol